TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02231827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
Study: NCT03318523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: Administered as specified in the treatment arm.
Study: NCT00501176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic and metalic stent inserion
Description: Patient randomizes to metal or plastic insertion prior to Whipple procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic and metalic stent inserion
Description: Patient randomizes to metal or plastic insertion prior to Whipple procedure
Study: NCT00478348

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prosthetic repair of abdominal incisional hernia
Description: Rives-Stoppa repair of incisional hernia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prosthetic repair of abdominal incisional hernia
Description: Rives-Stoppa repair of incisional hernia
Study: NCT01991626

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: micronutrient powder

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: micronutrient powder

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: micronutrient powder (containing FeSO4), phytase

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: micronutrient powder (containing FeSO4), phytase

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron pyrophosphate (FePP)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron pyrophosphate (FePP)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron pyrophosphate (FePP)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron sulphate

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron sulphate

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron sulphate
Study: NCT00591890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
Study: NCT05263752

Intervention type: DEVICE
Intervention: ERCP with NvisionVLE® Imaging Low Profile System
Description: Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with NvisionVLE® Imaging Low Profile System
Study: NCT04326270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal interface
Description: Randomized to initial interface of nCPAP prongs or infant cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal interface
Description: Randomized to initial interface of nCPAP prongs or infant cannula
Study: NCT05225246

Intervention type: OTHER
Intervention: Data collection on reasons for unplanned readmission to the University Hospital Basel within 30 days of leaving the hospital
Description: Descriptive analysis of the reasons for unplanned readmissions after cardiac surgery and predictive factors for unplanned readmissions and validation of risk scores

Intervention type: OTHER
Intervention: Data collection on reasons for unplanned readmission to the University Hospital Basel within 30 days of leaving the hospital
Description: Descriptive analysis of the reasons for unplanned readmissions after cardiac surgery and predictive factors for unplanned readmissions and validation of risk scores
Study: NCT06578962

Intervention type: OTHER
Intervention: Phase 1: short intensive treatment phase
Description: During the treatment phase (phase 1), all subjects of the study applied the tested product RV3438G, thrice a week, for 2 weeks.

Intervention type: OTHER
Intervention: Phase 1: short intensive treatment phase
Description: During the treatment phase (phase 1), all subjects of the study applied the tested product RV3438G, thrice a week, for 2 weeks.

Intervention type: OTHER
Intervention: Phase 1: short intensive treatment phase
Description: During the treatment phase (phase 1), all subjects of the study applied the tested product RV3438G, thrice a week, for 2 weeks.

Intervention type: OTHER
Intervention: Phase 2 : Tested product RV3438G associated with gentle balancing shampoo
Description: During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the gentle balancing shampoo RD1089O was applied twice a week alternately with the RV3438G shampoo, for 8 weeks.

Intervention type: OTHER
Intervention: Phase 2 : Tested product RV3438G associated with neutral shampoo
Description: During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the neutral shampoo RD0057H was applied twice a week alternately with the RV3438G shampoo, for 8 weeks.

Intervention type: OTHER
Intervention: Phase 2 : neutral shampoo
Description: During maintenance phase (phase 2):~the neutral shampoo RD0057H was applied thrice a week for 8 weeks.
Study: NCT03528538

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlphaFen fenugreek 400 mg
Description: A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlphaFen fenugreek 500 mg
Description: A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rice flour in a vegetable/ cellulose capsule
Study: NCT02176551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 0405
Description: Product 0405 will be administered topically twice daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Product 0405
Description: Placebo for Product 0405 will be administered topically twice daily for 28 days.
Study: NCT01911039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T Cells
Study: NCT03298347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg/kg of caffeine
Description: 80mg/kg of caffeine is given to treat AOP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg/kg of caffeine
Description: 20mg/kg of caffeine is given to treat AOP
Study: NCT01087346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading Information
Description: Reading information about risk factors for obesity among children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Information
Description: Reading information about risk factors for obesity among children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Information
Description: Reading information about risk factors for obesity among children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Information
Description: Reading information about risk factors for obesity among children
Study: NCT02828722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled light and noise
Description: Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled light and noise
Description: Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled nutrition
Description: In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached.
Study: NCT03725917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy protocol
Description: The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
Study: NCT03031938

Intervention type: DRUG
Group type: OTHER
Intervention: Investigational medical product (IMP) administered in parent study
Description: IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
Study: NCT04110769

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: next generation sequencing
Description: the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: next generation sequencing
Description: the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
Study: NCT01464671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Anticoagulation during percutaneous coronary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Anticoagulation during percutaneous coronary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Anticoagulation during percutaneous coronary intervention
Study: NCT01022671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotecan
Description: 3.0 mg/m2, Day 1, 8, 15 every 4 weeks
Study: NCT02811302

Intervention type: DEVICE
Group type: OTHER
Intervention: Capnostream Monitor
Description: Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
Study: NCT04368533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livionex Dental Gel
Description: The subjects will brush their teeth with Livionex Dental Gel twice a day for up to 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A standard children's toothpaste containing 1500 ppm fluoride
Description: The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
Study: NCT04110769

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: following next generation sequencing
Description: The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
Study: NCT01672541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dating Matters Comprehensive Approach
Description: The Dating Matters Comprehensive Approach includes:~6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Safe Dates Approach
Description: Safe Dates curriculum for 8th grade students
Study: NCT02782559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Color and size matched to active drug (sildenafil)
Study: NCT02087488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupuncture(AA)
Description: Auricular acupoints: Shenmen (TF4), Heart (CO15), Subcortex (AT4), modifying points according to different patterns.~Auricular attachment material: disposable Seirin Pyonex Needle Seirin Pyonex Needle manufacturer: Seirin Corporation, a Japanese company. Medical Device Certification number: No. 15500BZZ00806000.~Treatment frequency: every 3 days.~Duration: 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo AA
Description: Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4、5), Tooth (LO1), Tonsil (LO7, 8, 9).~Auricular attachment material: the disposable Pyonex Zero Needle Pyonex Zero Needle manufacturer: Seirin Corporation, a Japanese company.~Treatment frequency: every 3 days.~Duration: 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Dosage form: tablet.~Dosage: 1 piece (3mg).~Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.~Production license: NO. H20100074 approved by the state.~Treatment frequency: 15 mins before going to bed everyday.~Duration: 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eszopiclone
Description: Dosage form: tablet.~Dosage: 1 piece (3mg).~Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.~Production license: NO. H20100074 approved by the state.~Treatment frequency: 15 mins before going to bed everyday.~Duration: 4 weeks.
Study: NCT00653133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound imaging
Description: Ultrasound guided techniques for placement of peripheral nerve block catheters for continuous infusion of local anesthetic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve stimulator
Description: either stimulating needle or stimulating catheter used for placement of catheter for continuous infusion of local anesthetic
Study: NCT01597570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Closure Device
Description: To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vascular Closure Device
Description: To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
Study: NCT02921984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel only: 80 mg/m2 on day one, every 21 days if

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed only: 500 mg/m2 on day one, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
Study: NCT03145454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalography helmet
Description: electroencephalography helmet with twelve electrodes will be performed during surgical gesture to determine the pain of child.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dermal electrode
Description: dermal electrode on the back of the hand will be performed during surgical gesture to determine the pain of child.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood pressure sensors
Description: blood pressure sensors on the finger will be performed during surgical gesture to determine the pain of child.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry glasses
Description: Pupillometry glasses will be performed during surgical gesture to determine the pain of child.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: Three electrodes electrocardiography on the chest will be performed during surgical gesture to determine the heart rate variability.
Study: NCT02761421

Intervention type: OTHER
Intervention: observation study
Description: observation study
Study: NCT03350789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Description: manual acupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral GB30) + electroacupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral EX-B2 (L4 \& L5), BL25, BL23, BL40, GB34), twice a week, for 4 weeks, common approaches for the treatment of chronic sciatica used by doctors of Korean medicine in Korea today

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: sham acupuncture without skin penetration(0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) (unilateral GB30) + placebo electroacupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) without electrical stimulation (unilateral EX-B2, BL25, BL23, BL40, GB34), twice a week, for 4 weeks
Study: NCT00704600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir
Description: Phase I:~* take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 0: PET-CT~Phase II:~* take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 7 biopsy~* day 7, 21 and week 15 :PET-CT + perfusion CT
Study: NCT02347774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 50 mcg BID eFlow (CS) nebulizer
Description: SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CS) nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 25 mcg BID eFlow (CS) nebulizer
Description: SUN-101 25 mcg BID eFlow (R) Closed System (CS) nebulizer
Study: NCT03583216

Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetic pregnancy
Description: Blood samples will be drawn before delivery to evaluate Factor XII level.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-diabetic pregnancy
Description: Blood samples will be drawn before delivery to evaluate Factor XII level.
Study: NCT02261493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (normal saline) injected into the protocol-specified areas on Day 1.
Study: NCT04117035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKRS) personalised procedure
Description: Personalised GKRS treatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GKRS standard care
Description: Standard GKRS treatment
Study: NCT00142493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 1.2ug/ml
Study: NCT02347774

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eFlow (CS) nebulizer
Description: Placebo BID eFlow (R) Closed System (CS) nebulizer
Study: NCT04087720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: intravenous (IV) infusion
Study: NCT00142493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiopental Sodium
Description: 2.0ug/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: 0.5ng/ml
Study: NCT00026117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BenFin

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Study: NCT00142493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: 60ng/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intralipid, saline, saline with multi-Vit solution
Study: NCT01868022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3052230
Description: A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
Study: NCT05836493

Intervention type: PROCEDURE
Intervention: Ring annuloplasty
Description: A prosthetic ring is implanted to treat tricuspid regurgitation

Intervention type: PROCEDURE
Intervention: Suture procedure
Description: Suture techniques such as Kay or De Vega are used to reduce tricuspid annulus in order to treat tricuspid regurgitation
Study: NCT02839551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simplified drug provocation test
Description: Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
Study: NCT01049048

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2500 IU Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No (0 IU) vitamin D3 added to cookie.